Chang Yul Lee

US Patent:

7923661, Apr 12, 2011

Filed:

Sep 5, 2007

Appl. No.:

11/850574

Inventors:

Chang Sup Lee - Boyds MD, US

International Classification:

D06F 75/00
D06F 75/02

US Classification:

219248, 219245, 219249, 38 75

Abstract:

The present invention features an iron being adapted to guide a user through an ironing task. In some embodiments, the iron comprises a plurality of fabric selector switches, a message controller, a speaker, a temperature sensor, and a microprocessor. In some embodiments, said fabric selector switches are operatively connected as inputs to said microprocessor, said temperature sensor is operatively connected to a sole plate of the iron to measure the temperature of the sole plate, and the temperature sensor is also operatively connected as inputs to said microprocessor.

US Patent:

D652648, Jan 24, 2012

Filed:

Feb 4, 2011

Appl. No.:

29/384865

Inventors:

Chang Sup Lee - Boyds MD, US

International Classification:

0601

US Classification:

D 6373

US Patent:

D658905, May 8, 2012

Filed:

Nov 2, 2011

Appl. No.:

29/405492

Inventors:

Chang Sup Lee - Boyds MD, US

International Classification:

0601

US Classification:

D 6373

US Patent:

D659423, May 15, 2012

Filed:

Nov 2, 2011

Appl. No.:

29/405494

Inventors:

Chang Sup Lee - Boyds MD, US

International Classification:

0601

US Classification:

D 6373

US Patent:

20090188805, Jul 30, 2009

Filed:

Jan 23, 2009

Appl. No.:

12/358628

Inventors:

Thomas P. Moffat - Gaithersburg MD, US
Chang Hwa Lee - Gaithersburg MD, US
Daniel Jossel - N. Potomac MD, US
Soo-Kil Kim - Seoul, KR

International Classification:

C25D 5/02

US Classification:

205119

Abstract:

A process for electrodepositing at least one ferromagnetic material into a three dimensional pattern within a substrate is provided. The process comprises providing a substrate material, dielectric or conductor, having a three dimensional recessed pattern in at least one outer surface thereof, dielectric substrate materials also having an electrical conductive seed layer at least within the three dimensional pattern. An electrolytic bath is prepared comprising at least one ferromagnetic material and at least one accelerating, inhibiting, or depolarizing additive. The at least one ferromagnetic material comprises at least one metal cation selected from the group consisting of Ni, Co, Fe, Fe, and combinations thereof. The substrate is placed into the electrolytic bath and the electrolytic bath contacts the conducting three dimensional pattern in the substrate or the conducting seed layer within the pattern on a dielectric substrate. A counter electrode is placed into the electrolytic bath. An electric current is passed through the electrolytic bath between the electrical conductive substrate or seed layer on the three dimensional substrate and the counter electrode. At least a portion of the ferromagnetic material is deposited into at least a portion of the three dimensional pattern wherein the at least one deposited ferromagnetic material is substantially void-free.

US Patent:

20110262502, Oct 27, 2011

Filed:

Jul 1, 2011

Appl. No.:

13/174939

Inventors:

Chang LEE - Bethesda MD, US
Tao Tom Du - North Potomac MD, US

Assignee:

Prairie Pharmaceuticals LLC - Bethesda MD

International Classification:

A61K 31/57
A61K 9/72
A61K 9/12
A61P 11/00
A61P 31/04
A61P 33/00
A61P 37/08
A61P 19/02
A61K 9/14
A61P 25/00
B82Y 5/00

US Classification:

424400, 514179, 424 46, 514171, 977775

Abstract:

The invention relates to 17-HPC pulmonary formulations for administration by inhalation comprising 17-HPC and a pharmaceutically acceptable excipient. Particle size reduction of 17-HPC is required for the pulmonary delivery, and can be achieved with a surfactant or water without the surfactant. Preferred pulmonary formulations include a powder blend comprising a therapeutically effective amount of at least one steroid hormone (progestogen) as a glucocorticoid sensitizer, and at least one pharmaceutically acceptable excipient, wherein the at least one steroid hormone (progestogen) has a particle size distribution profile ranging from about one nanometer to about ten microns in the powder blend.

US Patent:

20210361674, Nov 25, 2021

Filed:

Apr 26, 2021

Appl. No.:

17/240698

Inventors:

- Shenzhen, CN
Chang LEE - Bethesda MD, US

Assignee:

Shenzhen Evergreen Therapeutics Co., Ltd. - Shenzhen

International Classification:

A61K 31/573
A61K 31/58
A61K 9/00
A61K 31/57
A61K 31/56

Abstract:

The present invention relates to the formulations, methods and kits for reducing cytokine interleukin-17 (IL-17 or IL-17A) levels in both broncheoalveolar lavage fluid (BALF) and blood/serum and/or for the inhibition of p38 mitogen activating protein kinase (MAPK) activity involving the use of 17α-hydroxyprogesterone caproate (17-OHPC) or derivatives thereof. The formulation may be in the form of an inhalant containing effective amounts of 17-OHPC, and the formulation may be used in a method to treat IL-17 cytokine and/or p38 MAPK mediated auto-immune and auto-inflammatory diseases. Such diseases may include glucocorticoid (GC) insensitive related diseases or conditions. In alternate embodiment, the formulation may include the combined use of budesonide (BUD) with 17-OPHC.

US Patent:

20160045396, Feb 18, 2016

Filed:

Sep 21, 2015

Appl. No.:

14/860578

Inventors:

Chang Lee - Bethesda MD, US
Tao Tom Du - North Potomac MD, US

Assignee:

PRAIRIE PHARMACEUTICALS LLC - Bethesda MD

International Classification:

A61J 3/02
A61K 9/16
A61K 9/00
A61K 31/573
A61K 31/58

Abstract:

The present invention relates to a pharmaceutical formulation powder that contains 17α-hydroxyprogesterone caproate (17-OHPC) powder and the method of producing the formulation produces particles that are suitable as an inhalant. The formulations, methods and kits of powdered 17-OHPC as taught herein may be used to reduce cytokine interleukin-17 (IL-17 or IL-17A) levels in both broncheoalveolar lavage fluid (BALF) and blood/serum and involve the inhibition of p38 mitogen activating protein kinase (MAPK) activity. The 17-OHPC powder formulation may be used in a method to treat IL-17 cytokine and/or p38 MAPK mediated auto-immune and auto-inflammatory diseases. Such diseases may include glucocorticoid (GC) insensitive related diseases or conditions. In alternate embodiment, the formulation may include the combined use of budesonide (BUD) and/or fluticasone with 17-OPHC.